According to market research “Global Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025 – Industry Insights by Drug (Opdivo, Keytruda, Tecentriq, Durvalumab, Avelumab), by Mechanism of Action (PD-1 Inhibitor, PD-L1 Inhibitor)” by P&S Market Research, the global programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors market is valued at an estimated $4,926.4 million in 2016, and it is expected to grow at a CAGR of 23.4% during 2017 – 2025.
The growth of the global market is largely driven by the increased investment and funding, strong pipeline, and improved safety and efficacy. BGB-A317, a Phase I therapeutic candidate of BeiGene Ltd., gained $75 million funding to continued development of targeted oncology candidate. PD-1 and PD-L1 inhibitors are applicable to a wider range of tumor types such as advanced or metastatic non-small cell lung cancer, renal cancer, melanoma and others. These inhibitors lower the rate of severe toxicities and immune-mediated side-effects. These are also convenient to administer, and yield a good response rate of any single-agent immunotherapy. This creates huge traction in pharmaceutical industry to develop PD-1 and PD-L1 inhibitors for treatment of different types of cancer.
Explore Report with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/pd1-and-pdl1-inhibitors-market
PD-1 and PD-L1 inhibitors are highly growing immunotherapies that are being used in oncology therapy area. The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47 drugs and there are approximately 245 active clinical studies. Currently, durvalumab from Astrazeneca and atezolizumab from Roche are among the most promising molecules in the pipeline, in terms of efficacy and safety. These molecules are in Phase III stage and expected to be launched in the coming years for the treatment of non-small cell lung cancer. There are many drugs in early stage of pipeline; thus, making PD1 and PDL1 inhibitors market very lucrative.
Among the different marketed PD-1 and PD-L1 inhibitor drugs, the largest revenue globally was generated from the sale of Opdivo in 2016. The global demand of Tecentriq is expected to witness high growth, primarily driven by the lack of approved competitor PD-L1 inhibitors drugs and high prevalence of urothelioma cancer.
Among the two mechanism of action, the PD-1 inhibitors were estimated to contribute 97.2% to the global PD-1 and PD-L1 inhibitors market in 2016. However, the approval of Tecentriq and expected approval of durvalumab and avelumab during forecast period will significantly increase PD-L1 inhibitors revenue contribution to the global market.
Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/healthcare
Some of the key players operating in the global market include Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and Merck KGaA.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Company Name: P&S Market Research
Contact Person: Abhishek, Executive – Client Partner
Phone: +1-888-778-7886 (USA/Canada Toll-Free)
Address:347, 5th Ave. #1402
City: New York City
Country: United States